Bicycle therapeutics provides data updates for three clinical programs and strategy overview at first r&d day

Cambridge, england & boston--(business wire)--bicycle therapeutics (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, is today hosting a research & development (r&d) day for investors and analysts in new york to provide clinical updates for bt8009, bt7480 and bt5528, and an overview of the company's strategy and pipeline opportunities. the company will also highlight the broad.
BCYC Ratings Summary
BCYC Quant Ranking